, Volume 11, Issue 3, pp 290–296 | Cite as

Somatostatin receptor expression in non-medullary thyroid carcinomas

  • Kalliopi Pazaitou-Panayiotou
  • Eva Tiensuu Janson
  • Triantafyllia Koletsa
  • Vassiliki Kotoula
  • Mats Stridsberg
  • Georgios Karkavelas
  • Georgia KarayannopoulouEmail author
Research paper



Peptide receptor radionuclide therapy (PRRT) is dependent upon binding of radiolabelled peptides to their respective receptor expressing cells. The main objective of this study was to characterize the expression of somatostatin receptor (SSTR) subtypes in non-medullary thyroid cancers in order to be able to recommend the use of PRRT as a treatment option in patients with progressive local or metastatic disease.


We constructed tissue microarrays from paraffin blocks prepared from 47 cases of non-medullary thyroid carcinomas and related normal thyroid tissue. Immunohistochemical staining was performed with five different polyclonal SSTR antibodies.


SSTR subtypes sst2 and sst3 were expressed in all non-medullary thyroid carcinomas, sst1 and sst5 in 75%, and sst4 in 38%. Coexpression of more than three subtypes was detected in 36 of the 47 cases. The expression of SSTR sub-types in normal thyroid tissue was low or absent.


Non-medullary thyroid carcinomas frequently express all SSTR subtypes. This expression provides a basis for further studies with the aim of exploring PRRT as a possible new treatment for iodine-131 refractory metastatic non-medullary thyroid carcinomas.

Key words

Thyroid carcinoma Somatostatin receptor Tissue microarray Immunohistochemistry 


  1. 1.
    Hundahl SA, Fleming ID, Fremgen AM, Menck HR, 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer 15: 2638–2648.CrossRefGoogle Scholar
  2. 2.
    Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium and the European Thyroid Cancer Taskforce. Eur J Endocrinol 154: 787–803.CrossRefGoogle Scholar
  3. 3.
    Sherman SI, 2003 Thyroid carcinoma. Lancet 8: 501–511.CrossRefGoogle Scholar
  4. 4.
    Maxon HR 3rd, Smith HS, 1990 Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am 19: 685–718.CrossRefGoogle Scholar
  5. 5.
    Janson ET, 2006 Treatment of neuroendocrine tumors with somatostatin analogs. Pituitary 9: 249–256.CrossRefGoogle Scholar
  6. 6.
    Teunissen JJ, Kwekkeboom DJ, Krenning EP, 2006 Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs. Trends Endocrinol Metab 17: 19–25.CrossRefGoogle Scholar
  7. 7.
    Garin E, Devillers A, Le Cloirec J, et al, 1998 Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake. Eur J Nucl Med 25: 687–694.CrossRefGoogle Scholar
  8. 8.
    Valli N, Catargi B, Ronci N, et al, 1999 Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy. Thyroid 9: 583–589.CrossRefGoogle Scholar
  9. 9.
    John M, Meyerhof W, Richter D, et al, 1996 Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut 38: 33–39.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR, 2011 Radiopeptide imaging and therapy in Europe. J Nucl Med 2: 42S–55S.CrossRefGoogle Scholar
  11. 11.
    Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V, 2012 Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine :DOI 10.1007/s12020-012-9631-1.Google Scholar
  12. 12.
    Klagge A, Krause K, Schierle K, Steinert F, Dralle H, Fuhrer D, 2010 Somatostatin receptor subtype expression in human thyroid tumours. Horm Metab Res 42: 237–240.CrossRefGoogle Scholar
  13. 13.
    Pisarek H, Stepien T, Kubiak R, Borkowska E, Pawlikowski M, 2009 Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohisto-chemical and molecular biology (RT-PCR) investigation. Thyroid Research 2: 1–8.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Sancak S, Hardt A, Singer J, et al, 2010 Somatostatin receptor 2 expression determined by immunohistochemistry in cold thyroid nodules exceeds that of hot thyroid nodules, papillary thyroid carcinoma, and Graves’ disease. Thyroid 20: 505–511.CrossRefGoogle Scholar
  15. 15.
    Papotti M, Kumar U, Volante M, Pecchioni C, Patel YC, 2001 Immunohistochemical detection of somatostatin receptor types 1–5 in medullary carcinoma of the thyroid. Clin Endocrinol (Oxf) 54: 641–649.CrossRefGoogle Scholar
  16. 16.
    Ludvigsen E, Olsson R, Stridsberg M, Janson ET, Sandler S, 2004 Expression and distribution of somatostatin receptor subtypes in the pancreatic islets of mice and rats. J Histochem Cytochem 52: 391–400.CrossRefGoogle Scholar
  17. 17.
    Taniyama Y, Suzuki T, Mikami Y, Moriya T, Satomi S, Sasano H, 2005 Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Endocr J 52: 605–611.CrossRefGoogle Scholar
  18. 18.
    Diakatou E, Kaltsas G, Tzivras M, Kanakis G, Papaliodi E, Kontogeorgos G, 2011 Somatostatin and dopamine receptor profile of gastroenteropancreatic neuroendocrine tumors: an immunohistochemical study. Endocr Pathol 22: 24–30.CrossRefGoogle Scholar
  19. 19.
    Pisarek H, Pawlikowski M, Kunert-Radek J, Kubiak R, Winczyk K, 2010 SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors. Folia Histochem Cytobiol 1: 142–147.Google Scholar
  20. 20.
    Gorges R, Kahaly G, Muller-Brand J, Macke H, Roser HW, Bockisch A, 2001 Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. Thyroid 11: 647–659.CrossRefGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2012

Authors and Affiliations

  • Kalliopi Pazaitou-Panayiotou
    • 1
  • Eva Tiensuu Janson
    • 2
  • Triantafyllia Koletsa
    • 3
  • Vassiliki Kotoula
    • 3
  • Mats Stridsberg
    • 4
  • Georgios Karkavelas
    • 3
  • Georgia Karayannopoulou
    • 3
    Email author
  1. 1.Department of Endocrinology - Endocrine OncologyTheagenio Cancer HospitalThessalonikiGreece
  2. 2.Department of Medical Sciences, Endocrine OncologyUppsala UniversityUppsalaSweden
  3. 3.Department of Pathology, Medical SchoolAristotle University of ThessalonikiThessalonikiGreece
  4. 4.Department of Medical Sciences, Clinical ChemistryUppsala UniversityUppsalaSweden

Personalised recommendations